Biotechnology Bulletin ›› 2019, Vol. 35 ›› Issue (6): 187-195.doi: 10.13560/j.cnki.biotech.bull.1985.2018-1049

Previous Articles     Next Articles

Research Advances on Afucosylated Trasuzumab

LEI Sha-sha1,2, ZHU Hong-yu2, ZHANG Guo-hua2, XU Ming-bo2, YANG Zhong-fan2, YAO Wen-bing1   

  1. 1. College of Life Science and Technology,China Pharmaceutical University,Nanjing 210009;
    2. Research of Recombinant Protein and Associated Ling-acting Preparation Engineering Technology of Beijing Shuanglu Pharmaceutical Co. Ltd.,Beijing 100143
  • Received:2018-12-10 Online:2019-06-26 Published:2019-07-08

Abstract: The breast cancer,among the most common malignant cancers in women,seriously endangers women’s life and health,due to its high mortality rate. HER2-positive breast cancer results in the highest incidence and mortality. The trastuzumab presents significant clinical efficacy in the treatment of HER2-positive breast cancer. However,as the consequence of drug resistance,the abnormal expression of HER2 and high medication cost,the trastuzumab encounters huge limitations in the real-world clinical use. It is found that the knockdown of core fucose in the Fc region area of the antibody significantly improves the ADCC effect of trastuzumab and its clinical efficacy. This manuscript mainly reviewed the means to knockdown the core fucose of trastuzumab and the associated clinical advantages of afucosylated trastuzumab,together with the other Fc region engineering methods to improve the ADCC effect of monoclonal antibody.

Key words: trastuzumab, afucosylated, ADCC, Fc region engineering